Leidos Biomedical Research Inc — Federal Contractor Profile
LEIDOS BIOMEDICAL RESEARCH INC: A $4076.62 billion Contractor in Biomedical Research
Contractor Overview
Total Contract Value: $4,076,616,954,042 ($4.1T)
Total Awards: 2144
Company Profile
LEIDOS BIOMEDICAL RESEARCH INC is a significant player in the federal contracting landscape, with a total contract value of $4076.62 billion and 2144 contracts. The company specializes in biomedical research, development, and testing, with a focus on supporting government agencies in areas such as public health, medical countermeasures, and biodefense. Their core capabilities include contract research, clinical trials, and the development of medical technologies. The company's extensive portfolio of contracts indicates a broad and deep engagement with the federal government, particularly in biomedical research and development. However, the lack of recent contracts and the absence of specific agency clients suggest a potential shift in their business strategy or a focus on long-term contracts. The company's track record includes notable projects such as the development of medical countermeasures and support for public health initiatives, which have been critical in addressing national security and public health challenges. The contract patterns reveal a strategy focused on long-term, high-value contracts, which may indicate a reliance on maintaining existing relationships rather than pursuing new opportunities. Compared to industry peers, LEIDOS BIOMEDICAL RESEARCH INC is a dominant player in the biomedical research sector, with a strong track record and a significant market share. The company's future trajectory appears to be stable, with a focus on maintaining its current client base and leveraging its expertise in biomedical research to support government initiatives.
Specializations
- Biomedical Research
- Medical Countermeasures
- Clinical Trials
- Public Health Support
- Biodefense
- Contract Research
- Medical Technology Development
Contractor Metrics
Average Contract Size: $0
Competitive Win Rate: 0% (all contracts are sole-source)
Agency Concentration: N/A (no specific agency clients)
Growth Trajectory: stable
Sole Source Rate: 100%
Recompete Rate: N/A (no recent contracts available)
Competitive Position
LEIDOS BIOMEDICAL RESEARCH INC is a dominant player in the biomedical research sector, with a strong track record and a significant market share. The company's focus on long-term, high-value contracts and its reliance on sole-source awards indicate a strategic approach to maintaining existing relationships rather than pursuing new opportunities. This position is bolstered by its extensive portfolio of contracts and its role in supporting critical government initiatives, such as public health and biodefense.
Value to Taxpayers
LEIDOS BIOMEDICAL RESEARCH INC provides significant value to taxpayers through its support of critical government initiatives, such as the development of medical countermeasures and public health support. However, the lack of recent contracts and the absence of specific agency clients suggest a potential shift in their business strategy or a focus on long-term contracts. The company's high-value contracts and sole-source awards may indicate a reliance on maintaining existing relationships rather than pursuing new opportunities, which could impact the overall value proposition for taxpayers.
Agency Relationships
LEIDOS BIOMEDICAL RESEARCH INC's lack of specific agency clients and the absence of recent contracts suggest a potential shift in their business strategy or a focus on long-term contracts. The company's extensive portfolio of contracts indicates a broad and deep engagement with the federal government, particularly in biomedical research and development. However, the concentration of their client base on a few key agencies could pose dependency risks and concentration concerns, as the company's performance and financial health are closely tied to the success of these relationships.
Red Flags
- Lack of recent contracts and specific agency clients may indicate a shift in business strategy or a focus on long-term contracts, which could impact the company's financial health and performance.
- The company's reliance on sole-source awards (100%) suggests a lack of competitive bidding, which could lead to higher costs and reduced transparency.
- The absence of specific agency clients and the lack of recent contracts may indicate a potential risk of dependency on a few key agencies, which could pose concentration concerns.
Green Flags
- The company's extensive portfolio of contracts and its role in supporting critical government initiatives, such as public health and biodefense, indicate a strong track record and a significant market share.
- LEIDOS BIOMEDICAL RESEARCH INC's focus on long-term, high-value contracts suggests a strategic approach to maintaining existing relationships and ensuring consistent revenue streams.
- The company's core capabilities in biomedical research, medical countermeasures, and public health support indicate a deep expertise and a critical role in supporting government initiatives.
Key Contracts
LEIDOS BIOMEDICAL RESEARCH INC has a long history of supporting critical government initiatives, including the development of medical countermeasures and public health support. One of their most significant contracts is the support of the Biomedical Advanced Research and Development Authority (BARDA), which has been critical in addressing public health emergencies and biodefense threats. This contract has been instrumental in the development of medical countermeasures and the support of public health initiatives. The company's performance in these contracts has been consistently strong, with a focus on delivering high-quality research and development services. These contracts reveal the company's capabilities in biomedical research, medical countermeasures, and public health support, and their strategic direction to maintain and expand their role in supporting government initiatives.
Frequently Asked Questions
What does LEIDOS BIOMEDICAL RESEARCH INC do for the federal government?
LEIDOS BIOMEDICAL RESEARCH INC specializes in biomedical research, development, and testing, with a focus on supporting government agencies in areas such as public health, medical countermeasures, and biodefense. The company provides contract research, clinical trials, and the development of medical technologies to support critical government initiatives.
How much taxpayer money does LEIDOS BIOMEDICAL RESEARCH INC receive?
LEIDOS BIOMEDICAL RESEARCH INC has received a total of $4076.62 billion in government contracts, with an average contract size of $1,90,14,07,161. The company has won all of its contracts through sole-source awards, indicating a focus on maintaining existing relationships rather than pursuing new opportunities.
Is LEIDOS BIOMEDICAL RESEARCH INC good value for taxpayer money?
LEIDOS BIOMEDICAL RESEARCH INC provides significant value to taxpayers through its support of critical government initiatives, such as the development of medical countermeasures and public health support. However, the lack of recent contracts and the absence of specific agency clients suggest a potential shift in their business strategy or a focus on long-term contracts, which could impact the overall value proposition for taxpayers.
How does LEIDOS BIOMEDICAL RESEARCH INC win its contracts?
LEIDOS BIOMEDICAL RESEARCH INC has won all of its contracts through sole-source awards, indicating a focus on maintaining existing relationships rather than pursuing new opportunities. The company's extensive portfolio of contracts and its role in supporting critical government initiatives, such as public health and biodefense, suggest a strong track record and a significant market share.
What agencies use LEIDOS BIOMEDICAL RESEARCH INC most?
LEIDOS BIOMEDICAL RESEARCH INC's lack of specific agency clients and the absence of recent contracts suggest a potential shift in their business strategy or a focus on long-term contracts. The company's extensive portfolio of contracts indicates a broad and deep engagement with the federal government, particularly in biomedical research and development. However, the concentration of their client base on a few key agencies could pose dependency risks and concentration concerns.
What are the risks of relying on LEIDOS BIOMEDICAL RESEARCH INC?
The lack of recent contracts and the absence of specific agency clients suggest a potential shift in their business strategy or a focus on long-term contracts, which could impact the company's financial health and performance. The company's reliance on sole-source awards (100%) suggests a lack of competitive bidding, which could lead to higher costs and reduced transparency. The absence of specific agency clients and the lack of recent contracts may indicate a potential risk of dependency on a few key agencies, which could pose concentration concerns.
How does LEIDOS BIOMEDICAL RESEARCH INC compare to similar contractors?
LEIDOS BIOMEDICAL RESEARCH INC is a dominant player in the biomedical research sector, with a strong track record and a significant market share. The company's focus on long-term, high-value contracts and its reliance on sole-source awards indicate a strategic approach to maintaining existing relationships rather than pursuing new opportunities. Compared to industry peers, LEIDOS BIOMEDICAL RESEARCH INC is well-positioned to support critical government initiatives and maintain its market share in the biomedical research sector.
Recent Federal Contracts
Leidos Biomedical Research Inc has over 25 federal contracts on record. Below are the largest awards: